Comorbidity and survival among women with ovarian cancer: evidence from prospective studies.
Comorbidity and survival among women with ovarian cancer: evidence from prospective studies.
复制标题
卵巢癌女性的合并症和生存率：前瞻性研究的证据
DOI：
10.1038/srep11720
复制
发表时间：
2015-06-29
影响因子：
4.6
通讯作者：
Wu QJ
中科院分区：
文献类型：
--
作者：
Jiao YS;Gong TT;Wang YL;Wu QJ
合并症和卵巢癌生存率之间的关系至今仍有争议。因此，我们进行了一项荟萃分析，总结了关于这一问题的前瞻性研究的现有证据。通过检索截至2015年1月底的PubMed、EMBASE和ISI Web of Science数据库，确定了相关研究。两名作者独立进行了合格性评价和数据提取。使用随机效应模型估计总生存期的汇总风险比（HR）和95%置信区间（CI）。本研究纳入了8项前瞻性研究，涉及12，681例卵巢癌病例。合并症存在与否的HR为1.20（95%CI = 1.11-1.30，n = 8），具有中度异质性（I2= 31.2%，P = 0.179）。此外，Charlson合并症指数最高类别与最低类别相比的汇总HR为1.68（95%CI = 1.50-1.87，n = 2），无异质性（I2= 0%，P = 0.476）。值得注意的是，在大多数按研究特征分层的亚组分析中观察到合并症对卵巢癌生存率的显著负面影响，以及是否对潜在混杂因素进行了调整。总之，这项荟萃分析的结果表明，潜在的合并症始终与卵巢癌患者生存率下降相关。管理这些患者时应考虑合并症。
The relationship between comorbidity and ovarian cancer survival has been controversial so far. Therefore, we conducted a meta-analysis to summarize the existing evidence from prospective studies on this issue. Relevant studies were identified by searching the PubMed, EMBASE and ISI Web of Science databases through the end of January 2015. Two authors independently performed the eligibility evaluation and data abstraction. Random-effects models were used to estimate summary hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival. Eight prospective studies involving 12,681 ovarian cancer cases were included in the present study. The summarized HR for presenceversusabsence of comorbidity was 1.20 (95% CI = 1.11–1.30, n = 8), with moderate heterogeneity (I2= 31.2%,P= 0.179). In addition, the summarized HR for the highest compared with the lowest category of the Charlson’s comorbidity index was 1.68 (95% CI = 1.50–1.87, n = 2), without heterogeneity (I2= 0%,P= 0.476). Notably, a significant negative impact of comorbidity on ovarian cancer survival was observed in most subgroup analyses stratified by the study characteristics and whether there was adjustment for potential confounders. In conclusion, the findings of this meta-analysis suggest that underlying comorbidity is consistently associated with decreased survival in patients with ovarian cancer. Comorbidity should be taken into account when managing these patients.
登录
查看更多内容
影响因子：
8.8
作者：
Jorgensen, T. L.;Hallas, J.;Friis, S.;Herrstedt, J.
通讯作者：
Herrstedt, J.
影响因子：
2
作者：
Hamling, Jan;Lee, Peter;Ambuehl, Mathias
通讯作者：
Ambuehl, Mathias
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
DOI：
10.1158/1055-9965.epi-13-0759-t
发表时间：
2013-12-01
影响因子：
3.8
作者：
Guan, Hong-Bo;Wu, Qi-Jun;Gong, Ting-Ting
通讯作者：
Gong, Ting-Ting
影响因子：
11.4
作者：
Anuradha, Satyamurthy;Webb, Penelope M.;Jordan, Susan J.
通讯作者：
Jordan, Susan J.